Agilent Technologies, whose advanced analytical and diagnostic solutions underpin everything from cancer treatment to ensuring the safety of food, water, and medicine, has secured $2.1B in new capital. The company designs and manufactures a wide array of tools and services critical for scientific research and quality control, helping customers discover new drug treatments and research infectious diseases.
With fiscal 2022 revenue of $6.85 billion, Agilent's global teams bring innovations to the forefront of science, providing unique expertise and support to optimize laboratories and resources for bringing great science to life.
